-
Analyst: Insys To Benefit As FDA Pushes Naloxone Access
Wednesday, December 19, 2018 - 12:07pm | 403Read More...As Insys Therapeutics Inc (NASDAQ: INSY) shifts from opioid therapies to cannabinoids and spray technology, one analyst sees an opportunity to buy in. The Rating Janney analyst Yun Zhong assumed coverage with a Buy rating and cut his price target from $16 to $11. The Thesis Insys forecasted at...
-
A Peek At Adamis Ahead Of FDA Approval
Thursday, June 15, 2017 - 9:05am | 301Read More...Adamis Pharmaceuticals Inc (NASDAQ: ADMP) may have a major catalyst on the way in the next several days. Adamis could be on the brink of a third ruling from the U.S. Food and Drug Administration related to its leading product candidate, a pre-filled epinephrine syringe that could serve as a low-...
-
What Makes Mylan's Newest EpiPen Lawsuit Different?
Monday, April 10, 2017 - 2:01pm | 900Read More...Mylan N.V. (NASDAQ: MYL), which has faced a plethora of lawsuits in the past over its EpiPen, is now being saddled with another lawsuit, although this time around the parties involved go beyond the company and the plaintiffs. EpiPen And Its Legal Tussle EpiPen, or an epinephrine auto injector is...
-
Teva Says Its Generic EpiPen Will Be 'Significantly Delayed'
Tuesday, March 1, 2016 - 2:53pm | 229Read More...Teva Pharmaceutical Industries Ltd (ADR) (NYSE: TEVA) announced in a regulatory filing on Monday that it has received notice from the U.S. Food and Drug Administration (FDA) related to its epinephrine. Teva said that the FDA identified "certain major deficiencies" and now expects its epinephrine...
